ECP 2019 Final Programme

LOOK BELOW THE SURFACE TO FIND OUT WHAT’S DRIVING THE TUMOR TRK FUSION PROTEINS ARE A PRIMARY ONCOGENIC DRIVER ACROSS MULTIPLE TUMORS IN ADULTS AND CHILDREN 1,2 THERE’S MORE TO SOME CANCERS THAN MEETS THE EYE LEARN MORE ABOUT TRK FUSION CANCER AT TRKCANCER.COM TRK, tropomyosin receptor kinase. References: 1 .Okimoto RA,BivonaTG.Tracking down response and resistance toTRK inhibitors. Cancer Discov . 2016;6(1):14-16. 2 .VaishnaviA,LeAT,Doebele RC.TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov .2015;5(1):25-34. © 2019 Bayer HealthCare Pharmaceuticals, Inc.All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. PP-LAR-ALL-0013-1 10/2018 PP-VIT-FR-0002-1 06/2019